Wyden Statement on Announcement of Finance Committee Hearing on the President’s Drug Pricing Blueprint

Webp adobestock 221016184
Adobe Stock

Wyden Statement on Announcement of Finance Committee Hearing on the President’s Drug Pricing Blueprint

The following press release was published by the United States Senate Committee on Finance Chairman's News on June 19, 2018. It is reproduced in full below.

Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued a statement after Chairman Orrin Hatch, R-Utah, announced a hearing to examine the prescription drug pricing system in the United States:

“The American public is clamoring for action that will lower their sky high prescription drug costs - I’m concerned the president’s plan falls short by asking questions instead of offering solutions and leaving the root causes of this critical issue unaddressed," Wyden said. “There is an opportunity here for bold action, but it requires Republicans in Congress to work with Democrats and the administration to enact lasting change that lowers drug prices to help families whose budgets are stretched too thin."

Source: US Senate Committee on Finance Chairman's News

More News